Hao Zhang
Direttore/Membro del Consiglio presso Ambio Pharmaceuticals
Posizioni attive di Hao Zhang
Società | Posizione | Inizio | Fine |
---|---|---|---|
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | Direttore/Membro del Consiglio | 08/10/2020 | - |
Storia della carriera di Hao Zhang
Precedenti posizioni note di Hao Zhang
Società | Posizione | Inizio | Fine |
---|---|---|---|
Goldman Sachs Gao Hua Securities Co., Ltd.
Goldman Sachs Gao Hua Securities Co., Ltd. Investment Banks/BrokersFinance Goldman Sachs Gao Hua Securities Co., Ltd. (GS-GHS) is a Beijing-based securities firm established in 2004 as a joint venture between the leading global investment banking, securities and investment management firm Goldman Sachs Group, Inc. (NYSE: GS) and the domestic securities firm Beijing Gao Hua Securities Co. Ltd., led by China-born banker Fang Fenglei. The Lenovo Group, China's largest computer manufacturer, was a key investor in GS-GHS, which was set-up through the acquisition of the operating license of the failed Hainan Securities. The presence of Goldman Sachs in Beijing dates back to 1993, and the creation of GS-GHS gave them a first-mover advantage in the Chinese securities market. GS-GHS offers a wide range of investment banking services to clients based in mainland China, including domestic securities brokerage and proprietary trading in equity, fixed income, currency and commodities. The firm underwrites locally-listed A-share transactions as well as RMB-denominated corporate bonds and convertible bonds. They also provide domestic financial advisory and other related services. The management team comprises Chinese and international investment bankers and securities professionals. | Corporate Officer/Principal | 01/07/2010 | 01/03/2012 |
THE CARLYLE GROUP INC. | Corporate Officer/Principal | 01/03/2012 | - |
Ambio Holdings, Inc.
Ambio Holdings, Inc. Pharmaceuticals: MajorHealth Technology Ambio Holdings, Inc. operates as a pharmaceutical company which focuses on complex peptides. It develops processes for manufacturing peptides at small to large scale as active pharmaceutical ingredients used in New Chemical Entities and generic peptides by clients worldwide. The company was founded by Chris J. Bai in 2014 and is headquartered in North Augusta, SC. | Direttore/Membro del Consiglio | 14/05/2019 | - |
Formazione di Hao Zhang
Fudan University | Undergraduate Degree |
The University of Chicago | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Cina | 3 |
Isole Cayman | 2 |
Posizioni
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 3 |
Finance | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
THE CARLYLE GROUP INC. | Finance |
Aziende private | 3 |
---|---|
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | Commercial Services |
Ambio Holdings, Inc.
Ambio Holdings, Inc. Pharmaceuticals: MajorHealth Technology Ambio Holdings, Inc. operates as a pharmaceutical company which focuses on complex peptides. It develops processes for manufacturing peptides at small to large scale as active pharmaceutical ingredients used in New Chemical Entities and generic peptides by clients worldwide. The company was founded by Chris J. Bai in 2014 and is headquartered in North Augusta, SC. | Health Technology |
Goldman Sachs Gao Hua Securities Co., Ltd.
Goldman Sachs Gao Hua Securities Co., Ltd. Investment Banks/BrokersFinance Goldman Sachs Gao Hua Securities Co., Ltd. (GS-GHS) is a Beijing-based securities firm established in 2004 as a joint venture between the leading global investment banking, securities and investment management firm Goldman Sachs Group, Inc. (NYSE: GS) and the domestic securities firm Beijing Gao Hua Securities Co. Ltd., led by China-born banker Fang Fenglei. The Lenovo Group, China's largest computer manufacturer, was a key investor in GS-GHS, which was set-up through the acquisition of the operating license of the failed Hainan Securities. The presence of Goldman Sachs in Beijing dates back to 1993, and the creation of GS-GHS gave them a first-mover advantage in the Chinese securities market. GS-GHS offers a wide range of investment banking services to clients based in mainland China, including domestic securities brokerage and proprietary trading in equity, fixed income, currency and commodities. The firm underwrites locally-listed A-share transactions as well as RMB-denominated corporate bonds and convertible bonds. They also provide domestic financial advisory and other related services. The management team comprises Chinese and international investment bankers and securities professionals. | Finance |
- Borsa valori
- Insiders
- Hao Zhang
- Esperienza